Targeting sphingosine kinase 1 in p53KO thymic lymphoma

Abstract

Sphingosine kinase 1 (SK1) is a key sphingolipid enzyme that is upregulated in several types of cancer, including lymphoma which is a heterogenous group of malignancies. Treatment for lymphoma has improved significantly by the introduction of new therapies; however, subtypes with tumor protein P53 (p53) mutations or deletion have poor prognosis, making it critical to explore new therapeutic strategies in this context. SK1 has been proposed as a therapeutic target in different types of cancer; however, the effect of targeting SK1 in cancers with p53 deletion has not been evaluated yet. Previous work from our group suggests that loss of SK1 is a key event in mediating the tumor suppressive effect of p53. Employing both genetic and pharmacological approaches to inhibit SK1 function in Trp53KO mice, we show that targeting SK1 decreases tumor growth of established p53KO thymic lymphoma. Inducible deletion of Sphk1 or its pharmacological inhibition drive increased cell death in tumors which is accompanied by selective accumulation of sphingosine levels. These results demonstrate the relevance of SK1 in the growth and maintenance of lymphoma in the absence of p53 function, positioning this enzyme as a potential therapeutic target for the treatment of tumors that lack functional p53.

Therapeutic Potential for Sphingolipids in Inflammatory Bowel Disease and Colorectal Cancer

“…Many sphingolipid mimetics have issues with solubility and delivery. Additionally, PK studies that have been conducted on sphingolipid inhibitors have revealed reduced stability in vivo and short plasma half-life [61,75,116]. Nanoliposomes are currently being explored to improve delivery and stability for several sphingolipid mimetics and inhibitors.…”